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Objective: In this study, we investigated the effects of radiotherapy 60 Gy in the setting of
concurrent chemo-radiotherapy for treating patients with Stages II–III esophageal cancer.
Methods: A total of 126 patients treated with 5-fluorouracilbased concurrent chemo-radiother-
apy between January 1998 and February 2008 were retrospectively reviewed. Among these
patients, 49 received a total radiation dose of ,60 Gy (standard-dose group), while 77 received
a total radiation dose of 60 Gy (high-dose group). The median doses in the standard- and
high-dose groups were 54 Gy (range, 45–59.4 Gy) and 63 Gy (range, 60–81 Gy), respectively.
Results: The high-dose group showed significantly improved locoregional control (2-year locor-
egional control rate, 69 versus 32%, P, 0.01) and progression-free survival (2-year progres-
sion-free survival, 47 versus 20%, P ¼ 0.01) than the standard-dose group. Median overall
survival in the high- and the standard-dose groups was 28 and 18 months, respectively (P ¼
0.26). In multivariate analysis, 60 Gy or higher radiotherapy was a significant prognostic factor
for improved locoregional control, progression-free survival and overall survival. No significant
differences were found in frequencies of late radiation pneumonitis, post-treatment esophageal
stricture or treatment-related mortality between the two groups.
Conclusions: High-dose radiotherapy of 60 Gy or higher with concurrent chemotherapy
improved locoregional control and progression-free survival without a significant increase of in
treatment-related toxicity in patients with Stages II– III esophageal cancer. Our study could
provide the basis for future randomized clinical trials.
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INTRODUCTION
Esophageal cancer has a poor prognosis due to high rates of
local recurrence and distant metastasis (1,2). About one half of
patients presented with locally advanced stage at the time of
diagnosis (3) and have a 5-year survival rate of ,30% after sur-
gical resection or multimodality therapy. In the past decade, nu-
merous single institutions and cooperative groups have
investigated the use of concurrent chemo-radiotherapy (CCRT)
as a deﬁnitive treatment or as a preoperative treatment for
patients with localized esophageal cancer. Deﬁnitive CCRT or
preoperative CCRT with surgery results in better survival than
single-modality treatments such as surgery or radiotherapy
(4–10). Consequently, the National Comprehensive Cancer
Network (NCCN) esophageal cancer guidelines recommend
preoperative CCRT or deﬁnitive CCRT for the patients with
Stages II or III esophageal cancer. However, in the setting of
deﬁnitive CCRT, the dose of radiotherapy requires further in-
vestigation. Generally, 45–50 Gy radiation dose is adequate to
control microscopic tumors, and 60 Gy or higher radiotherapy
is required to control gross tumors at conventional fractionation
(11–13). In the Radiation Therapy Oncology Group (RTOG)
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trial 94-05 study, which compared 50.4 Gy radiotherapy with
64.8 Gy radiotherapy in a CCRT setting, there was no signiﬁ-
cant difference in overall survival (OS) and locoregional
control (LRC) between the high- and standard-dose treatment
arms (14). However, Zhang et al. (15) reported that radiation
doses .51 Gy improved LRC, disease-free survival and sur-
vival in patients treated with 5-ﬂuorouracil (5-FU) based
chemotherapy. These authors also reported a positive correl-
ation between radiation dose and LRC. However, in this study,
the role of 60 Gy or higher dose radiotherapy was unclear as
only 26 patients received radiotherapy .51 Gy.
In this study, we investigated the effects of 60 Gy or higher
radiotherapy with concurrent chemotherapy on LRC,
progression-free survival (PFS) and OS in patients with
Stages II–III esophageal cancer.
PATIENTS ANDMETHODS
PATIENTS
Between January 1998 and February 2008, a total of 264
patients with Stages II–III esophageal cancer were treated by
CCRT at our institution. One hundred and twenty-six of
the 264 patients treated with CCRT were included for this
study. The remaining patients were excluded from this analysis
for the following reasons: (i) they received low-dose radio-
therapy with palliative intent (n ¼ 36); (ii) they underwent
esophagectomy after CCRT (n ¼ 47); (iii) they had a recurrent
tumor and received CCRT for salvage purposes (n ¼ 35) and
(iv) they had other primary tumors (n ¼ 20). Ultimately, the
medical records of total 126 patients treated with CCRT were
retrospectively reviewed for this study.
Pretreatment evaluation included a medical history, physic-
al examination focusing on performance status and a history
of dysphagia. Laboratory studies included a complete blood
cell count and blood chemistries. For stage workup, barium
swallow, chest computerized tomography (CT) and transeso-
phageal endoscopic ultrasonography were performed. To
evaluate if there was distant metastasis, patients were evalu-
ated by 18F-ﬂuorodeoxyglucose positron emission tomog-
raphy (FDG-PET), bone scans and abdomen CT.
RADIOTHERAPY
Radiotherapy was delivered using 10 MV photons starting on
Day 1 of chemotherapy. A conventional fractionation schedule
(5 days per week, 1.8–2.0 Gy/fraction daily) and cone-down
technique were used in all patients. Prior to the 2000s, a two-
dimensional plan was used, and thereafter, a three-dimensional
plan. The primary tumor was conﬁrmed by correlation with
barium swallow and CT images in two-dimensional plans. In
three-dimensional plans, gross tumor volume was delineated
using CT–PET fusion on a Pinnacle radiotherapy treatment
planning system (Phillips Medical Systems, Andover, MA,
Table 1. Chemotherapy regimens
Characteristic No. of patients (%) P value
Standard dose (n ¼ 49) High dose (n ¼ 77)
Regimen
5-FU þ cisplatin 44 (90) 68 (88) 0.22
5-FU monotherapy 5 (10) 5 (7)
Others 0 (0) 4 (5)
Median dose of chemotherapy
5-FU (mg/m2/week)a 800 (750–1250) 800 (750–1250) 0.16
Cisplatin (mg/m2/week)a 20 (10–25) 20 (10–25) 0.67
Maintenance chemotherapy
Yes 25 (53) 57 (74) 0.01
No 23 (47) 20 (26)
No. of chemotherapy cycles
2 Cycles 23 (47) 20 (26) 0.09
3 Cycles 2 (4) 4 (5)
4 Cycles 3 (6) 18 (23)
5 Cycles 21 (43) 35 (46)
5-FU, 5-ﬂuorouracil; CCRT, concurrent chemo-radiotherapy.
aThe values were expressed as the median with range.
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USA). The initial target volume encompassed the primary
tumor with a margin of at least 5 cm above and below the
tumor and 2 cm radially. The initial target volume was treated
with 30.6–45 Gy (median dose, 36 Gy) before cone down. To
reduce lung irradiation, anterior–posterior parallel opposite
ﬁelds were used in these phases. In the boost phase of radiation,
the ﬁnal target volume encompassed the primary tumor with a
margin of at least 2 cm above and below the tumor and 2 cm ra-
dially. To restrict the spinal cord dose, left–right parallel op-
posite ﬁelds or two posterior oblique ﬁelds were used in
two-dimensional plans. In three-dimensional plans, three to ﬁve
multi-ports ﬁelds were used. The total radiation dose ranged
between 43.2 and 75.6 Gy (median dose, 63 Gy). The spinal
cord dose was limited to within 45 Gy, and the lung volume
exposed to 25 Gy was limited to 20%.
CHEMOTHERAPY
All patients received 5-FU-based chemotherapy, and 89% of
the patients (n ¼ 112) were treated with both 5-FU and cis-
platin. 5-FU was administered at 750–1250 mg/m2 daily as a
continuous infusion using a portable electronic pump on Days
1–4 and cisplatin was administered at 40–100 mg/m2 on Day
1, and during radiotherapy. Ten patients (8%) received 5-FU
monotherapy. Among the rest of four patients, three patients
received 5-FU, docetaxel and cisplatin, and one patient received
5-FU and carboplatin. The mean dose of 5-FU per week was
higher in the high-dose group; however, this result was not stat-
istically signiﬁcant (846 mg/m2/week versus 815 mg/m2/week,
P ¼ 0.16). Mean doses of cisplatin per week in both groups
were 19 mg/m2/week. Each cycle of chemotherapy was
repeated every 28 days, and two cycles of chemotherapy were
administered with radiotherapy. After CCRT, 66% of patients
(n ¼ 83) received maintenance chemotherapy for 1–6 cycles
(median, four cycles). The frequency of patients who received
maintenance chemotherapy was signiﬁcantly higher in the
high-dose group than the standard-dose group. The details of
chemotherapy are summarized in Table 1.
FOLLOW-UP
During radiotherapy, patients were examined weekly to
monitor treatment-related toxicities and general condition.
Barium swallow, chest CT and FDG-PET were performed
within 2 months after completion of radiotherapy. Treatment
response was evaluated according to response evaluation cri-
teria in solid tumors (RECIST; version 1.1) (16) with some
modiﬁcations. A clinically complete response was deﬁned as
no histologic evidence of cancer from endoscopic biopsy or
no pathologic FDG uptake on FDG-PET on follow-up visits.
Partial response was deﬁned as a reduction in tumor size of
.30% on chest CT and endoscopy. No response was deﬁned
as a reduction in tumor size of ,30%, no reduction in size or
increased tumor size. Sites of local failure were allocated to
one of three categories based on the pattern of failure;
(i) ‘central failure’, occurring within the ﬁnal radiotherapy
ﬁeld; (ii) ‘marginal failure’, within the initial radiotherapy
ﬁelds, but outside of the ﬁnal radiotherapy ﬁeld and (iii) ‘out-
ﬁeld failure’ occurring outside of the initial radiotherapy ﬁeld.
Survival duration was calculated from the date of initiation of
CCRT to that of the ﬁrst occurrence of the considered event
(locoregional recurrence, distant metastasis or death).
STATISTICAL ANALYSIS
Late radiation pneumonitis, which is developed 90 days after
the completion of radiotherapy, was scored according to the
RTOG late radiation morbidity scoring system. Other
treatment-related toxicities were graded according to the
common toxicity criteria for adverse events (version 4.0).
Patients were grouped by total radiation dose (60 and
,60 Gy). Statistical analyses were conducted using SPSS 18
(SPSS Inc., Chicago, IL, USA). Pearson’s x2 test was used to
assess measures of association in frequency tables. Difference
Table 2. Patient characteristics
Characteristic No. of patients (%) P value
Standard dose (n ¼ 49) High dose (n ¼ 77)
Age (years) 0.44
Median 65 66
Range 50–80 30–79
Sex 0.74
Male 45 (92) 72 (93)
Female 4 (8) 5 (7)
Performance status 0.15
KPS 90–100 31 (63) 38 (49)
KPS 60–80 18 (37) 39 (51)
Pathology 0.84
SCC 45 (92) 72 (93)
AdenoCa 3 (6) 3 (4)
Unknown 1 (2) 2 (3)
Tumor location 0.13
Cervical 1 (2) 9 (12)
Upper thoracic 10 (20) 14 (18)
Middle thoracic 24 (49) 41 (53)
Lower thoracic 14 (29) 13 (17)
Primary tumor size 0.86
5 cm 25 (51) 41 (53)
.5 cm 24 (49) 36 (37)
Stage ,0.01
II 17 (35) 9 (12)
III 32 (65) 68 (88)
KPS, Karnofsky performance status; SCC, squamous cell carcinoma;
AdenoCa, adenocarcinoma.
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of intensities of chemotherapy between the groups was com-
pared using independent samples t-tests. Survival was ana-
lyzed using the Kaplan–Meier estimates, and the log-rank test
was used to assess the equality of the survival function across
groups. Prognostic factors of survival were analyzed by uni-
variate and multivariate analyses using Cox’s proportional
hazards model.
RESULTS
PATIENT CHARACTERISTICS AND CLINICAL PROFILE
Of the 126 patients included in our study, 49 received radi-
ation doses of ,60 Gy (standard-dose group) and 77 received
radiation doses of 60 Gy (high-dose group). The median ra-
diation dose received by the standard-dose group was 54 Gy
(range, 45–59.4 Gy) while that of the high-dose group was
63 Gy (range, 60–75.6 Gy). Pretreatment patient and tumor
characteristics of the two groups are listed in Table 2. There
were no statistically signiﬁcant differences in age, gender, per-
formance status, histologic subtype, tumor location or tumor
size between the two groups. However, the proportion of
Stage III patients was higher in the high-dose group than in
the standard-dose group (88 versus 65%, P, 0.01).
SURVIVAL AND DISEASE CONTROL
For surviving patients, the median follow-up times of the
standard-dose group and the high-dose group were 28 months
(range, 14–115) and 38 months (range, 15–81), respectively.
Of 65 patients who died after completion of radiotherapy,
Figure 1. Kaplan–Meier plot of (A) overall survival, (B) locoregional control (LRC), (C) distant metastasis-free survival and (D) progression-free survival,
according to radiation dose.
Table 3. Patterns of treatment failure
Failure pattern No. of patients (%) P value
Standard dose (n ¼ 49) High dose (n ¼ 77)
Local recurrence 27 (55) 20 (26) ,0.01
Central failure 20 (41) 12 (16) ,0.01
Marginal failure 2 (4) 2 (3) 0.64
Outﬁeld failure 5 (10) 6 (8) 0.75
Distant metastasis 11 (22) 26 (34) 0.23
Total 34 (69) 38 (49) 0.03
Jpn J Clin Oncol 2014;44(6) 537
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54 patients (43%) died from disease progression, eight
patients (6%) from treatment-related mortality and three
patients (2%) from other causes (two from cardiac failure and
one from falling down injury). Median OS for the high- and
the standard-dose groups was 28 and 18 months, respectively.
Two-year OS rates for the high- and the standard-dose groups
were 52.4 and 45.2%, respectively (P ¼ 0.26) (Fig. 1A).
However, the high-dose group had a signiﬁcantly better 2-year
local control rate (69 versus 32%, P, 0.01) and PFS (47
versus 20%, P ¼ 0.01) than the standard-dose group, as
shown in Fig. 1B and D. Two-year distant metastasis-free sur-
vival (DMFS) rate was not signiﬁcantly different between the
two groups (66% in the high-dose group versus 70% in the
standard-dose group, P ¼ 0.41) (Fig. 1C).
The complete, partial and no-response rates in the standard-
dose group were 39, 53 and 8%, respectively, while these rates
were 53, 42 and 5%, respectively, in the high-dose group. The
complete response rate was greater in the high-dose group
than the standard-dose group, but this result was not statistical-
ly signiﬁcant (P ¼ 0.14).
PATTERNS OF FAILURE
Locoregional failure rates for the high- and standard-dose
groups were 26 and 55%, respectively (P, 0.01). The central
failure rate for the high-dose group was signiﬁcantly lower
than the standard-dose group (16 versus 41%, P, 0.01).
Marginal failure rates and outﬁeld failure rates for the groups
were not signiﬁcantly different. The rate of distant metastasis
for all patients was 29%, and it was 34 and 22% for the high-
and standard-dose groups, respectively; however this differ-
ence was not statistically signiﬁcant (P ¼ 0.23). These data
are shown in Table 3.
TREATMENT-RELATED TOXICITIES
Nine patients (18%) in the standard-dose group and 18
patients (23%) in the high-dose group developed late radiation
pneumonitis, and incidences of radiation pneumonitis were
not different between the groups (P ¼ 0.66). Of nine patients
who showed radiation pneumonitis in the standard-dose
group, three, four one and one patient experienced Grade 1, 2,
4 and 5 radiation pneumonitis, respectively. In the high-dose
group, eight, ﬁve, three and two patients showed Grade 1, 2, 3
and 4 radiation pneumonitis, respectively. The incidences of
Grade 3 radiation pneumonitis in the standard-dose group
and the high-dose group were 4 and 6%, respectively. This dif-
ference was not statistically signiﬁcant (P ¼ 0.71).
Frequencies of post-radiotherapy esophageal stenosis in
both two groups were 29%, respectively. When incidences of
Table 4. Univariate analysis of prognostic factors
Factor Locoregional control Progression-free survival Overall survival
HR 95% CI P value HR 95% CI P value HR 95% CI P value
Age 60 years 0.86 0.44–1.65 0.64 0.98 0.57–1.69 0.95 0.96 0.55–1.70 0.90
Male gender 5.21 0.71–38.4 0.10 2.92 0.92–9.35 0.07 3.92 0.96–16.1 0.06
KPS 90–100 (versus 60–80) 0.75 0.42–1.34 0.33 0.57 0.35–0.91 0.02 0.42 0.25–0.70 ,0.01
Tumor in lower thoracic 0.75 0.36–1.56 0.45 0.8 0.45–1.44 0.47 0.60 0.31–1.18 0.14
Squamous cell type 0.88 0.31–2.46 0.81 0.92 0.40–2.12 0.84 0.69 0.30–1.60 0.39
Stage II (versus Stage III) 0.58 0.25–1.37 0.21 0.62 0.32–1.21 0.16 0.50 0.24–1.04 0.07
Radiation dose 60 Gy 0.36 0.2–0.64 ,0.01 0.55 0.35–0.88 0.01 0.76 0.46–1.25 0.27
Tumor size .5 cm 1.05 0.59–1.87 0.87 1.15 0.72–1.82 0.56 1.40 0.86–2.29 0.18
CI, conﬁdence interval.
Table 5. Multivariate analysis of prognostic factors
Factor Locoregional control Progression-free survival Overall survival
HR 95% CI P value HR 95% CI P value HR 95% CI P value
Male gender 5.18 0.70–38.5 0.13 2.70 0.83–8.70 0.10 3.17 0.76–13.3 0.11
KPS 90–100 (versus 60–80) 0.64 0.35–1.16 0.14 0.54 0.33–0.88 0.01 0.40 0.24–0.68 ,0.01
Stage II (versus Stage III) 0.35 0.15–0.86 0.02 0.47 0.23–0.94 0.03 0.39 0.18–0.85 0.02
Radiation dose 60 Gy 0.25 0.13–0.46 ,0.01 0.40 0.24–0.65 ,0.01 0.47 0.27–0.81 0.01
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Grade 3 or higher radiotherapy-related toxicities including
esophageal stenosis, hemorrhage and ﬁstula were compared
between the two groups, four (8.2%) radiotherapy-related
toxicities were observed in the standard-dose group versus
eight (10.4%) in the high-dose group (P ¼ 0.75). Grade 5
radiotherapy-related toxicities occurred in one patient (2.1%)
in the standard-dose group and in three patients (3.9%) in the
high-dose group (P ¼ 1.00).
There were two treatment-related death (4%) in the
standard-dose group and six treatment-related deaths (7.8%)
in the high-dose group. Of these seven treatment-related
deaths, three patients were due to chemotherapy-related tox-
icity, and one patient was due to radiation pneumonitis. Of the
remaining four deaths, three patients occurred due to esopha-
geal bleeding, and one due to tracheoesophageal ﬁstula.
PROGNOSTIC FACTORS
The results of univariate analysis for LRC, PFS and OS are
summarized in Table 4. High-dose radiotherapy (60 Gy)
signiﬁcantly affected both LRC and PFS. Good performance
status [Karnofsky performance status (KPS) 90–100] was a
favorable prognostic factor that affected PFS and OS. In multi-
variate analysis (Table 5), the high-dose radiotherapy
(60 Gy) was a signiﬁcant prognostic factor for improved
LRC, PFS and OS. Stage II disease was also a signiﬁcantly fa-
vorable prognostic factor for LRC, PFS and OS. Good per-
formance status (KPS 90–100) was a signiﬁcant prognostic
factor for improved PFS and OS.
DOSE–RESPONSE RELATIONSHIP
Two-year LRC rates according to total radiation dose are
shown in Fig. 2. The relationship between total radiation dose
and LRC rate showed a positive correlation for a total radi-
ation dose ranging between 45 and 65 Gy. However, patients
who received 65 Gy or higher radiotherapy did not show a sig-
niﬁcant improvement in LRC.
DISCUSSION
In the present study, we compared treatment outcomes between
high-dose radiotherapy (60 Gy) and standard-dose radiother-
apy (,60 Gy) in the setting of CCRT for Stages II–III esopha-
geal cancer. We demonstrated that high-dose radiotherapy
improved LRC and PFS without a signiﬁcant increase in
treatment-related mortalities or toxicities. Furthermore, in
multivariate analysis, high-dose radiotherapy was a signiﬁcant
prognostic factor for improved LRC, PFS and OS. However,
distant metastasis was more frequent in the high-dose group
than the standard-dose group despite the improved LRC of the
high-dose group, although this difference was not statistically
signiﬁcant. The reason of higher distant metastasis rate in the
high-dose group is unclear. However, higher proportion of
Stage III patients in the high-dose group may have contributed,
in part, to higher distant metastasis in the high-dose group,
because intensity of chemotherapy was not lower in the high-
dose group than the standard-dose group.
Although NCCN esophageal cancer guidelines recommend
radiation doses of 50 or 50.4 Gy for deﬁnitive CCRT, radiation
dose escalation for treating esophageal cancer should be
studied further. The NCCN esophageal cancer radiation dose
recommendations are based on the results of the RTOG trial
94-05. RTOG trial 94-05 compared treatment response to
CCRT using 64.8 versus 50.4 Gy radiotherapy in patients with
Stages I–III squamous cell carcinoma (85%) or adenocarcin-
oma (15%) (14). This trial failed to show that high-dose radio-
therapy with concurrent chemotherapy had any advantages over
standard-dose radiotherapy with concurrent chemotherapy.
Treatment-related deaths were more frequent in the high-dose
arm than the standard-dose arm, and patients in the high-dose
arm tended to have a worse prognosis. However, 7 of the 11
deaths in the high-dose arm occurred in patients who received
50.4 Gy or less; therefore, high-dose radiation was not respon-
sible for the increased mortality in this group. The potential
beneﬁts of high-dose radiotherapy for esophageal cancer
should, therefore, not be ignored based only on this study. The
standard-dose arm in RTOG 94-05 had similar treatment out-
comes as the standard-dose group in the present study with
regard to median survival (18 versus 18 months) and 2-year sur-
vival rate (40 versus 45.2%). In contrast, the high-dose arm in
RTOG 94-05 showed a worse prognosis than the high-dose
group in the present study (the median survival, 13 versus 28
months).
In Japan, CCRT was introduced in the early 1990s, and the
regimen of 60 Gy radiotherapy in 30 fractions with a 2-week
planned break is widely used (17–20). The Japan Clinical
Oncology Group (JCOG) 9906 trial was a Phase II study to
evaluate the efﬁcacy of CCRT with cisplatin and 5-FU for
Stages II– III esophageal squamous cell carcinoma. Patients
were treated with radiotherapy as described above, and the
median survival and 3-year survival rates were 29 months and
44.7%, respectively (20). These survival results are compar-
able to the survival results obtained for patients in our high ra-
diation dose group.
Figure 2. Two-year LRC rates according to total radiation dose. Error bars
show standard error. *P, 0.05 in log-rank test.
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A recent randomized clinical trial comparing surgery alone
with chemoradiation followed by surgery in patients with
T1N1 or T2-3N0-1 esophageal cancer showed that demon-
strated preoperative chemoradiotherapy improved survival
among patients with potentially curable esophageal or esopha-
gogastric junction tumor (7). In this study, chemoradiation fol-
lowed by surgery showed excellent outcomes with median OS
of 49.4 months. However, two randomized clinical trials and a
recent meta-analysis, which compared chemoradiation alone
with chemoradiation followed by surgery failed to beneﬁt of
surgery on OS, while addition of surgery to chemoradiation
improved local control (21–23).
Due to retrospective nature of the current study, there are
several limitations to this study. First limitation of this study
is the possibility of underestimating treatment-related toxici-
ties. Second limitation is unbalance of patient characteristics
between the groups. Proportion of Stage III patients was
higher in the high-dose group than the standard-dose group
and as a result, the effect of high-dose radiotherapy on
DMFS and OS could not be exactly identiﬁed. Third limita-
tion is that dosages and cycles of chemotherapy were various
according to patients. Although mean doses of 5-FU and cis-
platin were not signiﬁcantly different between the groups,
the possibility that the intensity of chemotherapy could inﬂu-
ence the outcomes of the groups cannot be excluded.
Moreover, we could not analyze the role of maintenance
chemotherapy, because it is possible that the patients with
good performance status or showing good treatment response
received maintenance chemotherapy. Therefore, we did not
analyze the effect of maintenance chemotherapy on progno-
sis. However, despite these limitations, radiotherapy of
60 Gy or higher with concurrent chemotherapy produced
better LRC and PFS without signiﬁcant increase of
treatment-related toxicities.
In conclusion, high-dose radiotherapy of 60 Gy or higher
with concurrent chemotherapy is an effective treatment option
for Stages II – III esophageal cancer. It improves LRC and
PFS and may also improve the survival of Stages II – III
esophageal cancer patients. Therefore, radiation dose escal-
ation in the setting of CCRT for esophageal cancer deserves
future randomized clinical trials.
Conﬂict of interest statement
None declared.
References
1. Herskovic A, Leichman L, Lattin P, et al. Chemo/radiation with and
without surgery in the thoracic esophagus: the Wayne State experience.
Int J Radiat Oncol Biol Phys 1988;15:655–62.
2. Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M.
Preoperative chemoradiation followed by transhiatal esophagectomy for
carcinoma of the esophagus: ﬁnal report. J Clin Oncol 1993;11:1118–23.
3. Kelsen D. Preoperative chemoradiotherapy for esophageal cancer. J Clin
Oncol 2001;19:283–5.
4. Smith TJ, Ryan LM, Douglass HO, Jr, et al. Combined chemoradiotherapy
vs. radiotherapy alone for early stage squamous cell carcinoma of the
esophagus: a study of the Eastern Cooperative Oncology Group. Int J
Radiat Oncol Biol Phys 1998;42:269–76.
5. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed
by surgery compared with surgery alone in squamous-cell cancer of the
esophagus. N Engl J Med 1997;337:161–7.
6. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality
therapy with cisplatin, ﬂuorouracil, radiotherapy, and surgery compared
with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol
2008;26:1086–92.
7. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J Med
2012;366:2074–84.
8. Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T. Deﬁnitive
chemoradiation for oesophageal cancer—a standard of care in patients
with non-metastatic oesophageal cancer. Clin Oncol (R Coll Radiol)
2011;23:182–8.
9. Araujo CM, Souhami L, Gil RA, et al. A randomized trial comparing
radiation therapy versus concomitant radiation therapy and chemotherapy
in carcinoma of the thoracic esophagus. Cancer 1991;67:2258–61.
10. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and
radiotherapy compared with radiotherapy alone in patients with cancer of
the esophagus. N Engl J Med 1992;326:1593–8.
11. Fletcher GH. Keynote address: the scientiﬁc basis of the present and
future practice of clinical radiotherapy. Int J Radiat Oncol Biol Phys
1983;9:1073–82.
12. Zelefsky MJ, Harrison LB, Fass DE, Armstrong JG, Shah JP, Strong EW.
Postoperative radiation therapy for squamous cell carcinomas of the oral
cavity and oropharynx: impact of therapy on patients with positive
surgical margins. Int J Radiat Oncol Biol Phys 1993;25:17–21.
13. Halperin EC, Perez CA, Brady LW. Perez and Brady’s Principles and
Practice of Radiation Oncology. 5th edn. Philadelphia: Wolters Kluwer
Health/Lippincott Williams &Wilkins 2008.
14. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy
Oncology Group 94–05) phase III trial of combined-modality therapy for
esophageal cancer: high-dose versus standard-dose radiation therapy.
J Clin Oncol 2002;20:1167–74.
15. Zhang Z, Liao Z, Jin J, et al. Dose-response relationship in locoregional
control for patients with stage II – III esophageal cancer treated with
concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys
2005;61:656–64.
16. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation
criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J
Cancer 2009;45:228–47.
17. Ohtsu A, Boku N, Muro K, et al. Deﬁnitive chemoradiotherapy for T4
and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin
Oncol 1999;17:2915–21.
18. Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between
deﬁnitive chemoradiotherapy and radical surgery in patients with T(2–
3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat
Oncol Biol Phys 2003;57:425–33.
19. Li G, Hu W, Wang J, et al. Phase II study of concurrent chemoradiation in
combination with erlotinib for locally advanced esophageal carcinoma.
Int J Radiat Oncol Biol Phys 2010;78:1407–12.
20. Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy
with 5-ﬂuorouracil and cisplatin for stage II-III esophageal squamous cell
carcinoma: JCOG Trial (JCOG 9906). Int J Radiat Oncol Biol Phys
2010;81:684–90.
21. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and
without surgery in patients with locally advanced squamous cell
carcinoma of the esophagus. J Clin Oncol 2005;23:2310–7.
22. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by
surgery compared with chemoradiation alone in squamous cancer of the
esophagus: FFCD 9102. J Clin Oncol 2007;25:1160–8.
23. Pottgen C, Stuschke M. Radiotherapy versus surgery within
multimodality protocols for esophageal cancer—a meta-analysis of the
randomized trials. Cancer Treat Rev 2012;38:599–604.
540 High-dose RT for esophageal cancer
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on D
ecem
ber 10, 2014
http://jjco.oxfordjournals.org/
D
ow
nloaded from
 
